Greta Wodarcyk, PhD, is a scientist and biotech executive with expertise bridging product development, preclinical/toxicology, CMC, and clinical operations with a record of successful regulatory filings and clinical operational efficiency. Currently, Greta is a Co-Founder and Principal of CatalystBio, a Global Life Sciences Advisory Firm dedicated to moving first-in-class, first-in-kind technologies off the bench and into the clinic.  Greta also serves as the COO and Co-Founder of BioSynthera, Inc., which is developing the next generation of therapeutics for clotting/bleeding disorders.  Prior to co-founding CatalystBio and BioSynthera, Greta was the Sr. Director of Clinical Operations and Program Development at COUR Pharmaceuticals, where she oversaw COUR’s platform product development and pipeline and led the company’s IND and clinical operations efforts. During her tenure at COUR, Greta opened four INDs and built out COUR’s internal clinical operations capabilities for executing early-phase studies. Before joining COUR, Greta was a post-doc at Northwestern University, where she worked in novel chemoprevention drug development and led several multi-disciplinary, translational research projects. Her peer-reviewed publications appeared in top-tier scientific journals such as Nature Biomedical Engineering and Proceedings of the National Academy of Sciences. Greta obtained her doctorate in biological sciences at Northwestern University, where she focused on the nanoscale epigenetic structure-function relationship of chromatin in cancer cell chemoevasion and the development of strategies to physiochemically target chromatin structure as a means of increasing chemotherapeutic efficacy. She received a Bachelor of Arts in chemistry and a Bachelor of Arts in music from St. Olaf College.